Cell Therapeutics makes $21 million placement on back of EMA verdict on pixantrone
This article was originally published in Scrip
Executive Summary
Cell Therapeutics, Inc. (CTI), the Seattle-based oncology biopharmaceutical firm is set to raise $19.95 million in a private placement that coincides with good news from the European Medicines Agency on its Pixuvri (pixantrone maleate) treatment for paediatric cancer.